相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella et al.
HEPATOLOGY (2023)
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Teresa Brevini et al.
NATURE (2023)
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD
Elizabeth M. Brunt et al.
JOURNAL OF HEPATOLOGY (2022)
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2022)
Breakthroughs in therapies for NASH and remaining challenges
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2022)
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration
Frank A. Anania et al.
HEPATOLOGY (2021)
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
Rod S. Taylor et al.
GASTROENTEROLOGY (2020)
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis
Natalia Pydyn et al.
PHARMACOLOGICAL REPORTS (2020)
Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019
Robert J. Wong et al.
JAMA NETWORK OPEN (2020)
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
Arun J. Sanyal et al.
HEPATOLOGY (2019)
Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study
Debashis Haldar et al.
JOURNAL OF HEPATOLOGY (2019)
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Michael Trauner et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
Rohit Loomba et al.
GASTROENTEROLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes et al.
HEPATOLOGY (2018)
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
Mazen Noureddin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Zobair M. Younossi et al.
HEPATOLOGY (2018)
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
Kirstine S. Tolbol et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
Toshihiro Goto et al.
SCIENTIFIC REPORTS (2018)
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Mehmet Sayiner et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
Hannes Hagstrom et al.
JOURNAL OF HEPATOLOGY (2017)
Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis
Mohammad Saeid Rezaee-Zavareh et al.
ANNALS OF HEPATOLOGY (2017)
Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
J. E. Edwards et al.
CTS-Clinical and Translational Science (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
F. Nevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Obeticholic Acid, a Farnesoid X Receptor Agonist, Improves Portal Hypertension by Two Distinct Pathways in Cirrhotic Rats
Len Verbeke et al.
HEPATOLOGY (2014)
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis
J. H. Hoofnagle et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Physiological and molecular biochemical mechanisms of bile formation
Vasiliy Ivanovich Reshetnyak
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration
Yoyo T. Y. Li et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
V Ratziu et al.
GASTROENTEROLOGY (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
R Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
分享论文
